News - Anti-Arthritics/Rheumatics


Popular Filters

70 to 94 of 297 results

Nuvo's partner Mallinckrodt to resubmit osteoarthritis treatment to US FDA


Canada's Nuvo Research (TSX: NRI) says that its licensing partner Mallinckrodt (NYSE: MNK) has successfully…

Anti-Arthritics/RheumaticsCovidienMallinckrodtNorth AmericaNuvo ResearchPennsaidPharmaceuticalRegulation

Simponi ARIA cleared by US FDA


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Biotech subsidiary has received US Food…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi ARIA

Pfizer gets Swiss nod for Xeljanz for rheumatoid arthritis


US drug giant Pfizer (NYSE: PFE) said its rheumatoid arthritis (RA) therapy Xeljanz (tofacitinib) has…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationTakeda NycomedXeljanz

Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis


Belgium's leading pharma company UCB (Euronext Brussels: UCB) said today (July 4) that it has granted…


Bioventus in-licenses exclusive rights to Pfizer's BMP portfolio


USA-based orthopedic healing specialist Bioventus, a spin out from the UK's Smith & Nephew to an Essex…

Anti-Arthritics/RheumaticsBioventusGlobalhyaluronic acidLicensingPfizerPharmaceutical

EMA's CHMP backs approval of first two monoclonal antibody biosimilars of blockbuster Remicade


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRegulationRemsima

Chugai gains Japanese approval for Perjeta and Bonviva


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats


An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

XOMA's partner Servier launches proof-of-concept clinical program for gevokizumab


US drug developer XOMA Corp (Nasdaq: XOMA) says that its development partner, French independent drugmaker…

Anti-Arthritics/RheumaticsgevokizumabInflammatory diseasesPharmaceuticalResearchServierXOMA Corp

Sandoz initiates Ph III trial for biosimilar Enbrel


Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…


Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors


Bazedoxifene, a drug approved in some countries to treat osteoporosis, has now been shown to stop the…


Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China


US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib


Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Generics triple-therapy just as effective as brand-name Enbrel, new study shows


Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…


Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study


US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso


French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

AstraZeneca returns fostamatinib program rights to Rigel


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Rigel Pharmaceuticals (Nasdaq: RIGL) today…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibLicensingPharmaceuticalResearchRigel Pharmaceuticals

GlaxoSmithKline buys rights to MorphoSys RA drug candidate for up to $577 million


German biotech firm MorphoSys (FSE: MOR) yesterday (June 3) saw its shares leap as much as 6%, as it…


AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments


Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

70 to 94 of 297 results

Back to top